Kristen Kluska Analyst PerformanceManaging Director, Biotechnology Equity Research Analyst at Cantor FitzgeraldKristen Kluska is a stock analyst at Cantor Fitzgerald focused in the healthcare sector, covering 23 publicly traded companies. Over the past year, Kristen Kluska has issued 38 stock ratings, including strong buy, buy, and hold recommendations. While full access to Kristen Kluska's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Kristen Kluska's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings63 Last 6 YearsBuy Recommendations82.26% 51 Buy RatingsCompanies Covered23 Unique Companies Ratings Distribution62RatingsDistribution of strong buy, buy, hold, and sell ratings by Kristen Kluska.RatingPercentageCount Strong Buy1.6%1 ratings Buy80.6%50 ratings Hold17.7%11 ratings Sell0.0%0 ratingsOut of 62 total stock ratings issued by Kristen Kluska at Cantor Fitzgerald, the majority (80.6%) have been Buy recommendations, followed by 17.7% Hold and 1.6% Strong Buy.Best & Worst CallsBest Call0000.0%CAPRMay 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%XFORMar 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ100.0% of companies on NASDAQ23 companiesKristen Kluska, an analyst at Cantor Fitzgerald, currently covers 23 companies listed on , with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageHealthcare22 companies95.7%Technology1 company4.3%Kristen Kluska of Cantor Fitzgerald specializes in stock coverage within the Healthcare sector, with additional focus on Technology companies.Coverage IndustriesIndustryPercentageBIOTECHNOLOGY19 companies82.6%PHARMACEUTICALS3 companies13.0%SOFTWARE1 company4.3% Kristen Kluska's Ratings History at Cantor Fitzgerald Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsRAREUltragenyx Pharmaceutical8/20/2026Boost Price Target$26.24$103.00Overweight$0.0000.00% ROICAPRCapricor Therapeutics8/14/2026Upgrade$4.21Overweight$0.0000.00% ROIMNPRMonopar Therapeutics8/13/2026Downgrade$114.90$119.00Neutral$0.0000.00% ROICAPRCapricor Therapeutics7/30/2026Downgrade$6.67$3.50Neutral$0.0000.00% ROICLDXCelldex Therapeutics7/22/2026Lower Price Target$35.66$61.00Overweight$0.0000.00% ROIPTCTPTC Therapeutics7/16/2026Boost Price Target$78.84$130.00Overweight$0.0000.00% ROISUPNSupernus Pharmaceuticals7/9/2026Boost Price Target$49.35$67.00Overweight$0.0000.00% ROIRNAAvidity Biosciences6/18/2026Initiated Coverage$12.48$25.00Overweight$0.0000.00% ROIZVRAZevra Therapeutics6/8/2026Boost Price Target$11.23$34.00Overweight$0.0000.00% ROIRAREUltragenyx Pharmaceutical5/21/2026Boost Price Target$23.32$96.00Overweight$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. SLNOSoleno Therapeutics5/19/2026Reiterated Rating$53.01Neutral$0.0000.00% ROISLNOSoleno Therapeutics4/6/2026Downgrade$52.20$53.00Hold$0.0000.00% ROIADMAADMA Biologics3/26/2026Reiterated Rating$9.63Neutral$0.0000.00% ROICAPRCapricor Therapeutics3/13/2026Set Price Target$33.42$62.00Overweight$0.0000.00% ROIRNACCartesian Therapeutics3/9/2026Upgrade$7.35$16.00Overweight$0.0000.00% ROIQUREuniQure3/2/2026Reiterated Rating$10.12$9.00Neutral$0.0000.00% ROIPTCTPTC Therapeutics2/20/2026Reiterated Rating$69.49Overweight$0.0000.00% ROIIRONDisc Medicine2/17/2026Lower Price Target$60.55$125.00Overweight$0.0000.00% ROIMNPRMonopar Therapeutics1/21/2026Reiterated Rating$71.23Overweight$0.0000.00% ROIEPRXEupraxia Pharmaceuticals1/15/2026Boost Price Target$8.43$19.00Overweight$0.0000.00% ROIQUREuniQure1/14/2026Reiterated Rating$21.50Overweight$0.0000.00% ROIFOLDAmicus Therapeutics12/19/2025Downgrade$14.24$14.50Hold$0.0000.00% ROIDBVTDBV Technologies12/17/2025Set Price Target$21.74$48.00$0.0000.00% ROIDBVTDBV Technologies12/15/2025Upgrade$18.29Strong-Buy$0.0000.00% ROIDBVTDBV Technologies12/14/2025Initiated Coverage$18.37$42.00Overweight$0.0000.00% ROIFULCFulcrum Therapeutics12/8/2025Boost Price Target$8.90$24.00Overweight$0.0000.00% ROILXEOLexeo Therapeutics12/1/2025Initiated Coverage$9.83$19.00Overweight$0.0000.00% ROILXEOLexeo Therapeutics11/20/2025Initiated Coverage$9.09$19.00Overweight$0.0000.00% ROITSHATaysha Gene Therapies11/14/2025Reiterated Rating$4.01$13.00Overweight$0.0000.00% ROIZVRAZevra Therapeutics11/6/2025Lower Price Target$9.32$24.00Overweight$0.0000.00% ROIRIGLRigel Pharmaceuticals11/5/2025Boost Price Target$37.75$38.00Neutral$0.0000.00% ROIIRONDisc Medicine10/17/2025Boost Price Target$91.22$153.00Overweight$0.0000.00% ROISUPNSupernus Pharmaceuticals9/30/2025Boost Price Target$47.82$63.00Overweight$0.0000.00% ROIQUREuniQure9/25/2025Boost Price Target$47.50$80.00Overweight$0.0000.00% ROIMNPRMonopar Therapeutics9/24/2025Reiterated Rating$72.90Overweight$0.0000.00% ROIRAREUltragenyx Pharmaceutical9/5/2025Reiterated Rating$31.38$105.00Overweight$0.0000.00% ROIPTCTPTC Therapeutics9/3/2025Reiterated Rating$54.87$118.00Overweight$0.0000.00% ROIMNPRMonopar Therapeutics8/27/2025Reiterated Rating$32.03$74.00Overweight$0.0000.00% ROIRAREUltragenyx Pharmaceutical8/6/2025Lower Price Target$26.83$105.00Overweight$00.0000.00% ROISUPNSupernus Pharmaceuticals8/6/2025Boost Price Target$41.99$46.00Overweight$00.0000.00% ROITrump's New Dollar (Ad)Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.Watch the free briefing and see the three steps to prepare todayRIGLRigel Pharmaceuticals8/6/2025Boost Price Target$27.64$32.00Neutral$00.0000.00% ROIPTCPTC7/29/2025Set Price Target$202.95$120.00Overweight$000.0000.00% ROIPTCTPTC Therapeutics7/29/2025Boost Price Target$48.86$120.00Overweight$00.0000.00% ROIEPRXEupraxia Pharmaceuticals7/24/2025Initiated Coverage$5.14$11.00Overweight$0.0000.00% ROIMNPRMonopar Therapeutics7/7/2025Initiated Coverage$35.87$74.00Overweight$00.0000.00% ROIFULCFulcrum Therapeutics5/15/2025Upgrade$5.63$10.00Overweight$0.0000.00% ROICAPRCapricor Therapeutics5/14/2025Reiterated Rating$7.77$30.00Overweight$00.0000.00% ROIPTCTPTC Therapeutics5/7/2025Lower Price Target$38.93$112.00Overweight$00.0000.00% ROIRIGLRigel Pharmaceuticals5/7/2025Boost Price Target$20.51$23.00Neutral$00.0000.00% ROITSHATaysha Gene Therapies4/28/2025Reiterated Rating$1.86$7.00Overweight$0.0000.00% ROISLNOSoleno Therapeutics3/27/2025Boost Price Target$48.97$123.00Overweight$00.0000.00% ROIXFORX4 Pharmaceuticals3/26/2025Reiterated Rating$7.98$90.00Overweight$0.0000.00% ROICAPRCapricor Therapeutics3/20/2025Reiterated Rating$13.86$30.00Overweight$00.0000.00% ROIIRONDisc Medicine3/18/2025Boost Price Target$51.27$132.00Overweight$00.0000.00% ROIADMAADMA Biologics3/4/2025Reiterated Rating$13.78$25.00Overweight$00.0000.00% ROIRAREUltragenyx Pharmaceutical2/26/2025Reiterated Rating$40.80$118.00Overweight$00.0000.00% ROIPTCTPTC Therapeutics2/3/2025Boost Price Target$49.16$113.00Overweight$00.0000.00% ROICLDXCelldex Therapeutics1/29/2025Reiterated Rating$24.23$67.00Overweight$00.0000.00% ROIRAREUltragenyx Pharmaceutical1/22/2025Reiterated Rating$42.28$118.00Overweight$00.0000.00% ROIPTCTPTC Therapeutics1/15/2025Lower Price Target$41.81$76.00Overweight$00.0000.00% ROIFOLDAmicus Therapeutics1/15/2025Reiterated Rating$9.21$21.00Overweight$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenCitigroupUBS GroupBarclaysRoyal Bank Of CanadaMorgan StanleyWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerDeutsche Bank AktiengesellschaftBMO Capital Markets Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
